Equities Analysts Offer Predictions for IOVA Q2 Earnings

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) – Research analysts at Zacks Research increased their Q2 2028 earnings estimates for shares of Iovance Biotherapeutics in a note issued to investors on Friday, June 26th. Zacks Research analyst Team now expects that the biotechnology company will earn ($0.05) per share for the quarter, up from their prior estimate of ($0.06). The consensus estimate for Iovance Biotherapeutics’ current full-year earnings is ($0.62) per share.

Iovance Biotherapeutics (NASDAQ:IOVA) last released its earnings results on Thursday, May 7th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.19). The company had revenue of $71.43 million during the quarter, compared to analyst estimates of $77.84 million. Iovance Biotherapeutics had a negative return on equity of 50.17% and a negative net margin of 123.92%.Iovance Biotherapeutics’s quarterly revenue was up 44.9% on a year-over-year basis. During the same period in the prior year, the company posted ($0.36) earnings per share.

IOVA has been the topic of several other research reports. Truist Financial upgraded Iovance Biotherapeutics to a “hold” rating in a research note on Wednesday, March 25th. UBS Group upped their price target on Iovance Biotherapeutics from $2.00 to $4.00 and gave the company a “neutral” rating in a research report on Thursday, March 5th. Chardan Capital cut their price target on Iovance Biotherapeutics from $16.00 to $14.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Iovance Biotherapeutics in a report on Monday, April 6th. Five analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, Iovance Biotherapeutics has a consensus rating of “Hold” and an average price target of $8.43.

Iovance Biotherapeutics Stock Down 4.6%

Iovance Biotherapeutics stock opened at $3.97 on Thursday. The firm has a 50 day moving average price of $3.86 and a 200-day moving average price of $3.40. Iovance Biotherapeutics has a twelve month low of $1.68 and a twelve month high of $5.63. The company has a market capitalization of $1.77 billion, a P/E ratio of -4.18 and a beta of 0.74.

Institutional Investors Weigh In On Iovance Biotherapeutics

Several hedge funds have recently added to or reduced their stakes in the company. State Street Corp boosted its stake in Iovance Biotherapeutics by 51.5% in the fourth quarter. State Street Corp now owns 20,161,445 shares of the biotechnology company’s stock worth $55,041,000 after buying an additional 6,851,486 shares in the last quarter. Palo Alto Investors LP grew its holdings in shares of Iovance Biotherapeutics by 122.1% during the 3rd quarter. Palo Alto Investors LP now owns 7,618,132 shares of the biotechnology company’s stock valued at $16,531,000 after purchasing an additional 4,188,803 shares during the last quarter. HRT Financial LP raised its position in Iovance Biotherapeutics by 1,078.3% in the 4th quarter. HRT Financial LP now owns 4,356,010 shares of the biotechnology company’s stock worth $11,891,000 after purchasing an additional 3,986,314 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Iovance Biotherapeutics by 202.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,777,344 shares of the biotechnology company’s stock worth $19,239,000 after purchasing an additional 3,869,617 shares during the last quarter. Finally, Vanguard Group Inc. lifted its stake in Iovance Biotherapeutics by 13.1% in the fourth quarter. Vanguard Group Inc. now owns 27,207,079 shares of the biotechnology company’s stock worth $74,275,000 after purchasing an additional 3,148,096 shares during the last quarter. Institutional investors own 77.03% of the company’s stock.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.